New
Studies Demonstrate Cost Effectiveness, Clinical Value in a Stent
Population and Validation of a Therapeutic Window using the VerifyNow
System
ME Newswire / Business Wire
SAN DIEGO - Tuesday, March 12th 2013
Accumetrics,
Inc., developer of the market-leading VerifyNow® System, announced the
presentation of a series of important data that solidifies the clinical
utility of platelet reactivity testing. Real world outcomes data in high
risk patients receiving stents, a cost effectiveness analysis, and
validation of a therapeutic window continue to demonstrate platelet
reactivity as a critical element for improving the quality of care for
the millions of patients on antiplatelet therapies worldwide.
In
an oral presentation, Craig I. Coleman, PharmD, Associate Professor of
Pharmacy at the University of Connecticut School of Pharmacy, discussed
data from his cost-effectiveness analysis, which demonstrated that using
a platelet reactivity driven antiplatelet therapy treatment strategy
was more cost-effective than using a universal approach of generic
clopidogrel in all PCI patients. This follows his recent presentation at
the 2013 annual Cardiovascular Research Technologies meeting in
Washington DC, where his presentation demonstrated that a platelet
reactivity driven antiplatelet strategy is also more cost-effective than
a universal strategy of giving the more potent inhibitor, ticagrelor,
to all PCI patients. In both analyses the VerifyNow System was used to
support the cost model.
“Antiplatelet
therapy has undergone a rapid evolution following the approval of two
potent and more costly agents and the recent generic availability of
clopidogrel,” said Dr. Coleman. “The results of our model may have
significant implications on which antiplatelet agents clinicians use in
PCI patients, by attempting to focus on reducing healthcare costs and
hospital readmission while improving the quality of patient care.”
Data
presented from University Hospitals of Cleveland demonstrated that
managing dual antiplatelet therapy (DAPT) and high on treatment platelet
reactivity using a VerifyNow P2Y12 platelet reactivity testing strategy
and treatment algorithms in ACS and other high risk PCI patients led to
a reduction in 30 day event rates to one which is equal to that of the
facility’s stable, elective PCI population.
“At
the Harrington Heart and Vascular Institute/University Hospitals of
Cleveland, we have been ahead of the curve regarding the use of platelet
reactivity testing in high risk patients, having utilized a
comprehensive platelet function testing management program for the last
two and a half years,” said Dr. Tom Lassar, Associate Director of the
Adult Cardiac Catheterization Laboratory and Interventional Cardiology
at University Hospitals, Case Western Reserve in Cleveland, OH.
“Incorporating platelet reactivity measurements in our decision making
provides us with invaluable information to make treatment management
decisions in our higher risk PCI patients. The data reinforces our
conviction that a platelet function testing program is improving the
quality of care for our PCI patients. We look forward to expanding our
platelet reactivity program to other facilities in the University
Hospitals System.”
The
association between high platelet reactivity and risk for subsequent
ischemic events has been well-characterized by numerous studies.
Additional analysis of ADAPT-DES, discussed at an industry expert
theater, has also validated the association between very low levels of
platelet reactivity and an increased risk of bleeding complications.
“The
concept of a therapeutic window for platelet reactivity has been
previously postulated,” stated Dr. Ajay J. Kirtane, MD, SM, Chief
Academic Officer of the Center for Interventional Vascular Therapy at
Columbia University Medical Center / NewYork-Presbyterian Hospital in
New York City. “In over 8500 patients, we were able to demonstrate that
patients in the lowest quintile of response [PRU of 0-94] receive
virtually no additional protection from ischemic events, but had a
significantly higher incidence of bleeding. Recognition of this finding
could potentially allow clinicians to minimize the risk of bleeding
complications for patients who are on potent antiplatelet therapies.”
The
continued focus on antiplatelet therapies, including a late breaking
clinical trial with phase III results from the first IV P2Y12 inhibitor
to potentially come to market, coupled with numerous platelet reactivity
presentations further illustrates the need for greater clarity on
optimal use of antiplatelet agents in patients with cardiovascular
disease.
“The
developments at ACC further reinforce the importance of the VerifyNow
System in clinical practice,” said Timothy Still, President and CEO of
Accumetrics. “We are anticipating strong growth for our market leading
platelet reactivity tests that provide critical information to aid in
managing the risks, benefits and cost of the chosen antiplatelet
treatment strategy. This data sets a path to provide additional guidance
for the clinical community to improve care for the millions of patients
on antiplatelet therapies.”
The
VerifyNow System is currently used in over 1000 facilities in the
United States and over 80 countries worldwide where antiplatelet
medications are prescribed to reduce the occurrence of future thrombotic
events such as heart attack and stroke.
About Accumetrics
Accumetrics
is committed to advancing medical understanding of platelet function
and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.
Accumetrics’
VerifyNow System is the first rapid and easy-to-use platform to help
physicians determine an individual’s response to multiple antiplatelet
agents. Addressing every major antiplatelet drug, including FDA-cleared
products for aspirin, P2Y12 inhibitors (e.g. clopidogrel) and GP
IIb/IIIa inhibitors, the VerifyNow System provides valuable information
to help physicians make informed clinical decisions. The VerifyNow P2Y12
Test and the VerifyNow PRUTest are whole blood assays used in the
laboratory or point of care setting to measure the level of platelet
P2Y12 receptor blockade. Additionally, the VerifyNow P2Y12 Test is
indicated outside the US for evaluating the risk for recurrent events in
cardiovascular patients.
For more information about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.
Contacts
Jakob Jakobsen
310-309-1003 (Office)
jjakobsen@biosector2.com
or
Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com
No comments:
Post a Comment